Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

New England Journal of Medicine

Volumn 327, Issue 1, 1992, Pages 28-35

  Lieschke, Graham J ^a   Burgess, Antony W ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADVANCED CANCER; BONE MARROW TOXICITY; BONE PAIN; DOSE RESPONSE; DRUG HYPERSENSITIVITY; HEMATOPOIESIS; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULITIS;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0026740918     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199207023270106     Document Type: Review

References (86)

1. Morstyn G, Burgess AW. Hemopoietic growth factors: a review. Cancer Res 1988; 48: 5624–37.
2. Metcalf D, Morstyn G. Colony-stimulating factors: general biology. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: J.B. Lippincott, 1991:417–44.
3. Groopman JE, Molina J-M, Scadden DT. Hematopoietic growth factors: biology and clinical applications. N Engl J Med 1989; 321: 1449–59.
4. Moore MAS. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 1991; 78: 1–19.
5. Witte ON. Steel locus defines new multipotent growth factor. Cell 1990; 63: 5–6.
6. Erratum, Cell 1990; 63: 1112.
7. Williams WJ, Nelson DA. Examination of the marrow. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. 4th ed. New York: McGraw-Hill, 1990:24–31.
8. Layton JE, Cebon JS, Morstyn G. Cytokine responses to febrile neutropenia. Exp Hematol 1991; 19: 506. abstract.
9. Watari K, Asano S, Shirafuji N, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989; 73: 117–22.
10. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990; 76: 1962–4.
11. Lieschke GJ, Dunn AR. Physiologic role of granulocyte colony stimulating factor: insights from in vivo studies. In: Proceedings of the Second International Symposium on Molecular Biology of Hematopoiesis (in press).
12. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339–44.
13. Lieschke GJ, Morstyn G. Role of G-CSF and GM-CSF in the prevention of chemotherapy-induced neutropenia. In: Mertelsmann R, Herrmann F, eds. Hematopoietic growth factors in clinical applications. New York: Marcel Dekker, 1990:191–223.
14. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–40.
15. Neupogen product monograph. Macclesfield, United Kingdom: Gardiner Caldwell Communications, 1991:41.
16. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70.
17. Simon RM. Design and conduct of clinical trials. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Vol. 1. Philadelphia: J.B. Lippincott, 1989:396–420.
18. Gough NM, Gough J, Metcalf D, et al. Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocytemacrophage colony stimulating factor. Nature 1984; 309: 763–7.
19. Wong GG, Witek JS, Temple PA, et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985; 228: 810–5.
20. Cantrell MA, Anderson D, Cerretti DP, et al. Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A 1985; 82: 6250–4.
21. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61–5.
22. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986; 319: 415–8.
23. Zsebo KM, Cohen AM, Murdock DC, et al. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 1986; 172: 175–84.
24. Neupogen. Thousand Oaks, Calif.: Amgen, 1991 (package insert).
25. Kitamura T, Tojo A, Kuwaki T, et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989; 73: 375–80.
26. Griffin JD, Sullivan R, Beveridge RP, Larcom P, Schlossman SF. Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors. Blood 1984; 63: 904–11.
27. Leukine. Seattle, Wash.: Immunex, 1991 (package insert).
28. Gillis S, Urdal DL, Clevenger W, et al. Production of recombinant human colony stimulating factors in yeast. Behring Inst Mitt 1988; 83: 1–7.
29. Mayer P, Lam C, Obenaus H, Liehl E, Besemer J. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Blood 1987; 70: 206–13.
30. Cebon J, Nicola N, Ward M, et al. Granulocytemacrophage colony stimulating factor from human lymphocytes: the effect of glycosylation on receptor binding and biological activity. J Biol Chem 1990; 265: 4483–91.
31. Moonen P, Mermod JJ, Ernst JF, Hirschi M, DeLamarter JF. Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast or animal cells. Proc Natl Acad Sci U S A 1987; 84: 4428–31.
32. Gribben JG, Devereux S, Thomas NSB, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335: 434–7.
33. Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7: 629–37.
34. Davey RT Jr, Davey VJ, Metcalf JA, et al. A phase I/II trail of zidovudine, interferon-α, and granulocytemacrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991; 164: 43–52.
35. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56: 809–13.
36. Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58: 64–9.
37. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667–72.
38. Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989; 7: 1554–62.
39. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82: 1454–61.
40. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414–22.
41. Lindemann A, Herrmann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989; 74: 2644–51.
42. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074–81.
43. Lieschke GJ, Maher D, Cebon J, et al. Effects of bacterially synthesized recombinant human granulocytemacrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989; 110: 357–64.
44. Lieschke GJ, Maher D, O'Connor M, et al. Phase I study of intravenously administered bacterially synthesized granulocytemacrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990; 50: 606–14.
45. Steward WP, Scarffe JH, Austin R, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions — a phase I dose-toxicity study. Br J Cancer 1989; 59: 142–5.
46. Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocytemacrophage colony-stimulating factor. J Clin Oncol 1989; 7: 159–67.
47. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocytemacrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988: 319: 593–8.
48. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocytemacrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194–8.
49. Phillips N, Jacobs S, Stoller R, Earle E, Przepiorka D, Shadduck RK. Effect of recombinant human granulocytemacrophage colony-stimulating factor on myelopoiesis in patients with refractory metastatic carcinoma. Blood 1989; 74: 26–34.
50. Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocytemacrophage colony-stimulating factor. J Clin Invest 1989; 83: 551–7.
51. Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocytemacrophage colony-stimulating factor. Blood 1989; 74: 2634–43.
52. Socinski MA, Cannistra SA, Sullivan R, et al. Granulocytemacrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood 1988; 72: 691–7.
53. Devereux S, Bull HA, Campos-Costa D, Saib R, Linch DC. Granulocyte macrophage colony stimulating factor induces changes in cellular adhesion molecule expression and adhesion to endothelium: in-vitro and in-vivo studies in man. Br J Haematol 1989; 71: 323–30.
54. Addison IE, Johnson B, Devereux S, Goldstone AH, Linch DC. Granulocytemacrophage colony-stimulating factor may inhibit neutrophil migration in vivo. Clin Exp Immunol 1989; 76: 149–53.
55. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor α and interferon in cancer patients. Blood 1989; 73: 643–6.
56. Sullivan R, Fredette JP, Socinski M, et al. Enhancement of Superoxide anion release by granulocytes harvested from patients receiving granulocytemacrophage colony-stimulating factor. Br J Haematol 1989; 71: 475–9.
57. Kaplan SS, Basford RE, Wing EJ, Shadduck RK. The effect of recombinant human granulocyte macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma. Blood 1989; 73: 636–8.
58. Nimer SD, Champlin RE, Golde DW. Serum cholesterol—lowering activity of granulocytemacrophage colony-stimulating factor. JAMA 1988; 260: 3297–300.
59. Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77: 2109–17.
60. Asano S, Shirafuji N, Watari K, et al. Phase I clinical study for recombinant human granulocyte colony-stimulating factor. Behring Inst Mitt 1988; 83: 222–8.
61. Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A 1989; 86: 9499–503.
62. Lord BI, Gurney H, Chang J, Thatcher N, Crowther D, Dexter TM. Haemopoietic cell kinetics in humans treated with rGM-CSF. Int J Cancer 1992; 50: 26–31.
63. Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocytemacrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056–63.
64. Wodzinski MA, Hampton KK, Reilly JT. Differential effects of G-CSF and GM-CSF in acquired chronic neutropenia. Br J Haematol 1991; 77: 249–50.
65. Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988; 109: 789–95.
66. Jaiyesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis. N Engl J Med 1991; 325: 587.
67. Brown SL, Hill E. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis. N Engl J Med 1991: 325: 587.
68. Devereux S, Linch DC, Campos Costa D, Spittle MF, Jelliffe AM. Transient leucopenia induced by granulocytemacrophage colony-stimulating factor. Lancet 1987; 2: 1523–4.
69. Villeval J-L, Duhrsen U, Morstyn G, Metcalf D. Effect of recombinant human granulocytemacrophage colony stimulating factor on progenitor cells in patients with advanced malignancies. Br J Haematol 1990; 74: 36–44.
70. Peters WP, Shogan J, Shpall EJ, Jones RB, Kim CS. Recombinant human granulocytemacrophage colony-stimulating factor produces fever. Lancet 1988; 1: 950.
71. Hazenberg BPC, Van Leeuwen MA, Van Rijswijk MH, Stern achéal, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocytemacrophage colony-stimulating factor: simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989; 74: 2769–70.
72. De Vries EGE, Willemse PHB, Biemsa B, Stern achéal, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991; 338: 517–8.
73. Stehle B, Weiss C, Ho AD, Hunstein W. Serum levels of tumor necrosis factor α in patients treated with granulocytemacrophage colony-stimulating factor. Blood 1990; 75: 1895–6.
74. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocytemacrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–8.
75. Hoekman K, von Blomberg-van der Flier BME, Wagstaff J, Drexhage HA, Pinedo HM. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541–2.
76. Logothetis CJ, Dexeus FH, Sella A, et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocytemacrophage colony-stimulating factor. J Natl Cancer Inst 1990; 82: 667–72.
77. Nathan FE, Besa EC. GM-CSF and accelerated hemolysis. N Engl J Med 1992; 326: 417.
78. Erratum, N Engl J Med 1992; 326: 904.
79. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989; 74: 1303–7.
80. Cebon J, Dempsey P, Fox R, et al. Pharmacokinetics of human granulocytemacrophage colony-stimulating factor using a sensitive immunoassay. Blood 1988; 72: 1340–7.
81. Motojima H, Kobayashi T, Shimane M, Kamachi S, Fukushima M. Quantitative enzyme immunoassay for human granulocyte colony stimulating factor (G-CSF). J Immunol Methods 1989; 118: 187–92.
82. Burgess AW, Begley CG, Johnson GR, et al. Purification and properties of bacterially synthesized human granulocytemacrophage colony stimulating factor. Blood 1987; 69: 43–51.
83. Cebon JS, Bury RW, Lieschke GJ, Morstyn G. The effects of dose and route of administration on the pharmacokinetics of granulocytemacrophage colony-stimulating factor. Eur J Cancer 1990; 26: 1064–9.
84. Cebon J, Lieschke GJ, Bury RW, Morstyn G. The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br J Haematol 1992; 80: 144–50.
85. Donahue RE, Wang EA, Kaufman RJ, et al. Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. In: Molecular biology of Homo sapiens. Vol. 51 of Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1986: 685–92.
86. Shadduck RK, Waheed A, Evans C, Sulecki M, Rosenfeld CS. Serum and urinary levels of recombinant human granulocytemacrophage colony-stimulating factor: assessment after intravenous infusion and subcutaneous injection. Exp Hematol 1990; 18: 601. abstract.